Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children ≥2 years with cystic fibrosis: 96-week interim results from a phase 3 open-label extension study

Journal of Cystic Fibrosis · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles